High susceptibility of metastatic cells derived from human prostate and colon cancer cells to TRAIL and sensitization of TRAIL-insensitive primary cells to TRAIL by 4,5-dimethoxy-2-nitrobenzaldehyde

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Kim, Hak Bong ^a   Kim, Mi Ju ^a   Kim, Dae Young ^a   Lee, Jae Won ^a   Bae, Jae Ho ^a   Kim, Dong Wan ^b   Kang, Chi Dug ^a   Kim, Sun Hee ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Changwon National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4,5 DIMETHOXY 2 NITROBENZALDEHYDE; ACTIN; CASPASE 3; CASPASE 8; CASPASE 9; CELL SURFACE RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DNA DEPENDENT PROTEIN KINASE; FLICE INHIBITORY PROTEIN; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 8; PROCASPASE 9; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PROTEIN MCL 1; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; 4,5-DIMETHOXY-2-NITROBENZALDEHYDE; BENZALDEHYDE DERIVATIVE; CFLAR PROTEIN, HUMAN; MYC PROTEIN, HUMAN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADVANCED CANCER; APOPTOSIS; ARTICLE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METASTASIS; ONCOGENE C MYC; PROSTATE CANCER; PROTEIN CLEAVAGE; RECEPTOR UPREGULATION; SENSITIZATION; CELL SURVIVAL; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL CULTURE; TUMOR CELL LINE; WESTERN BLOTTING;

APOPTOSIS; BENZALDEHYDES; BLOTTING, WESTERN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DNA-ACTIVATED PROTEIN KINASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED;

EID: 79955017535     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-46     Document Type: Article

References (47)

1. Rosa DD, Ismael G, Lago LD, Awada A. Molecular-targeted therapies: lessons from years of clinical development. Cancer Treat Rev 2008, 34:61-80. 10.1016/j.ctrv.2007.07.019, 17826917.
2. Cusack JC. Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver. Ann Surg Oncol 2003, 10:852-862. 10.1245/ASO.2003.07.518, 14527902.
3. Sorscher SM. Biological therapy update in colorectal cancer. Expert Opin Biol Ther 2007, 7:509-519. 10.1517/14712598.7.4.509, 17373902.
4. Mimeault M, Batra SK. Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies. Anticancer Agents Med Chem 2010, 10:137-151. 2997522, 20184544.
5. Rudmik LR, Magliocco AM. Molecular mechanisms of hepatic metastasis in colorectal cancer. J Surg Oncol 2005, 92:347-359. 10.1002/jso.20393, 16299807.
6. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O. TRAIL in cancer therapy: present and future challenges. Expert Opin Ther Targets 2007, 11:1299-1314. 10.1517/14728222.11.10.1299, 2976473, 17907960.
7. Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005, 23:9394-9407. 10.1200/JCO.2005.02.2889, 16361639.
8. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008, 263:14-25. 10.1016/j.canlet.2008.02.003, 18329793.
9. Fernandez T, Torres MJ, R RP, Fuentes MS, Robles S, Mayorga C, Blanca M. Decrease of selective immunoglobulin E response to amoxicillin despite repeated administration of benzylpenicillin and penicillin V. Clin Exp Allergy 2005, 35:1645-1650. 10.1111/j.1365-2222.2005.02378.x, 16393332.
10. Nieminen AI, Partanen JI, Klefstrom J. c-Myc blazing a trail of death: coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc. Cell Cycle 2007, 6:2464-2472. 10.4161/cc.6.20.4917, 17914284.
11. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene 2008, 27:6462-6472. 10.1038/onc.2008.312, 18955973.
12. Nieminen AI, Partanen JI, Hau A, Klefstrom J. c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosis. EMBO J 2007, 26:1055-1067. 10.1038/sj.emboj.7601551, 1852827, 17268552.
13. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004, 5:501-512. 10.1016/S1535-6108(04)00113-8, 15144957.
14. Um JH, Kwon JK, Kang CD, Kim MJ, Ju DS, Bae JH, Kim DW, Chung BS, Kim SH. Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J Pharmacol Exp Ther 2004, 311:1062-1070. 10.1124/jpet.104.070938, 15273254.
15. An J, Yang DY, Xu QZ, Zhang SM, Huo YY, Shang ZF, Wang Y, Wu DC, Zhou PK. DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein. Mol Cancer 2008, 7:32. 10.1186/1476-4598-7-32, 2383926, 18426604.
16. Qiao M, Iglehart JD, Pardee AB. Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation. Cancer Res 2007, 67:5293-5299. 10.1158/0008-5472.CAN-07-0877, 17545609.
17. Kim SH, Ricci MS, El-Deiry WS. Mcl-1: a gateway to TRAIL sensitization. Cancer Res 2008, 68:2062-2064. 10.1158/0008-5472.CAN-07-6278, 18381408.
18. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007, 12:66-80. 10.1016/j.ccr.2007.05.006, 17613437.
19. Ricci MS, Jin Z, Dews M, Yu D, Thomas-Tikhonenko A, Dicker DT, El-Deiry WS. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 2004, 24:8541-8555. 10.1128/MCB.24.19.8541-8555.2004, 516765, 15367674.
20. Iijima S, Teraoka H, Date T, Tsukada K. DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation of c-Myc oncoprotein. Eur J Biochem 1992, 206:595-603. 10.1111/j.1432-1033.1992.tb16964.x, 1597196.
21. Lane D, Robert V, Grondin R, Rancourt C, Piche A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007, 121:1227-1237. 10.1002/ijc.22840, 17534891.
22. Larribere L, Khaled M, Tartare-Deckert S, Busca R, Luciano F, Bille K, Valony G, Eychene A, Auberger P, Ortonne JP, et al. PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ 2004, 11:1084-1091. 10.1038/sj.cdd.4401475, 15243584.
23. Asakuma J, Sumitomo M, Asano T, Hayakawa M. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 2003, 63:1365-1370.
24. Xu J, Zhou JY, Wei WZ, Wu GS. Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells. PLoS One 2010, 5:e10226. 10.1371/journal.pone.0010226, 2856686, 20419107.
25. Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 2004, 279:41189-41196. 10.1074/jbc.M406731200, 15262962.
26. Teraoka H, Yumoto Y, Watanabe F, Tsukada K, Suwa A, Enari M, Nagata S. CPP32/Yama/apopain cleaves the catalytic component of DNA-dependent protein kinase in the holoenzyme. FEBS Lett 1996, 393:1-6. 10.1016/0014-5793(96)00842-3, 8804412.
27. Durant S, Karran P. Vanillins--a novel family of DNA-PK inhibitors. Nucleic Acids Res 2003, 31:5501-5512. 10.1093/nar/gkg753, 206453, 14500812.
28. Seo SB, Hur JG, Kim MJ, Lee JW, Kim HB, Bae JH, Kim DW, Kang CD, Kim SH. TRAIL sensitize MDR cells to MDR-related drugs by down-regulation of P-glycoprotein through inhibition of DNA-PKcs/Akt/GSK-3beta pathway and activation of caspases. Mol Cancer 2010, 9:199. 10.1186/1476-4598-9-199, 2918570, 20663232.
29. Park SJ, Bijangi-Vishehsaraei K, Safa AR. Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells. Int J Biochem Mol Biol 2010, 1:90-100. 2953951, 20953314.
30. Hall MA, Cleveland JL. Clearing the TRAIL for Cancer Therapy. Cancer Cell 2007, 12:4-6. 10.1016/j.ccr.2007.06.011, 17613431.
31. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002, 2:764-776. 10.1038/nrc904, 12360279.
32. Hueber AO, Zornig M, Lyon D, Suda T, Nagata S, Evan GI. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 1997, 278:1305-1309. 10.1126/science.278.5341.1305, 9360929.
33. Klefstrom J, Arighi E, Littlewood T, Jaattela M, Saksela E, Evan GI, Alitalo K. Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. EMBO J 1997, 16:7382-7392. 10.1093/emboj/16.24.7382, 1170338, 9405367.
34. Han J, Goldstein LA, Gastman BR, Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 2006, 281:10153-10163. 10.1074/jbc.M510349200, 16478725.
35. Kataoka T, Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-kappaB signaling pathway. Mol Cell Biol 2004, 24:2627-2636. 10.1128/MCB.24.7.2627-2636.2004, 371124, 15024054.
36. Shintani S, Mihara M, Li C, Nakahara Y, Hino S, Nakashiro K, Hamakawa H. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci 2003, 94:894-900. 10.1111/j.1349-7006.2003.tb01372.x, 14556663.
37. Stronati L, Gensabella G, Lamberti C, Barattini P, Frasca D, Tanzarella C, Giacobini S, Toscano MG, Santacroce C, Danesi DT. Expression and DNA binding activity of the Ku heterodimer in bladder carcinoma. Cancer 2001, 92:2484-2492. 10.1002/1097-0142(20011101)92:9<2484::AID-CNCR1598>3.0.CO;2-7, 11745306.
38. Tonotsuka N, Hosoi Y, Miyazaki S, Miyata G, Sugawara K, Mori T, Ouchi N, Satomi S, Matsumoto Y, Nakagawa K, et al. Heterogeneous expression of DNA-dependent protein kinase in esophageal cancer and normal epithelium. Int J Mol Med 2006, 18:441-447.
39. Moll U, Lau R, Sypes MA, Gupta MM, Anderson CW. DNA-PK, the DNA-activated protein kinase, is differentially expressed in normal and malignant human tissues. Oncogene 1999, 18:3114-3126. 10.1038/sj.onc.1202640, 10340383.
40. An J, Xu QZ, Sui JL, Bai B, Zhou PK. Downregulation of c-myc protein by siRNA-mediated silencing of DNA-PKcs in HeLa cells. Int J Cancer 2005, 117:531-537. 10.1002/ijc.21093, 15929110.
41. Puduvalli VK, Sampath D, Bruner JM, Nangia J, Xu R, Kyritsis AP. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 2005, 10:233-243. 10.1007/s10495-005-6078-3, 15711939.
42. Lee YJ, Froelich CJ, Fujita N, Tsuruo T, Kim JH. Reconstitution of caspase-3 confers low glucose-enhanced tumor necrosis factor-related apoptosis-inducing ligand cytotoxicity and Akt cleavage. Clin Cancer Res 2004, 10:1894-1900. 10.1158/1078-0432.CCR-03-0136, 15041704.
43. Affar EB, Germain M, Winstall E, Vodenicharov M, Shah RG, Salvesen GS, Poirier GG. Caspase-3-mediated processing of poly(ADP-ribose) glycohydrolase during apoptosis. J Biol Chem 2001, 276:2935-2942. 10.1074/jbc.M007269200, 11053413.
44. Graham KL, Gustin KE, Rivera C, Kuyumcu-Martinez NM, Choe SS, Lloyd RE, Sarnow P, Utz PJ. Proteolytic cleavage of the catalytic subunit of DNA-dependent protein kinase during poliovirus infection. J Virol 2004, 78:6313-6321. 10.1128/JVI.78.12.6313-6321.2004, 416498, 15163725.
45. Kim SH, Um JH, Dong-Won B, Kwon BH, Kim DW, Chung BS, Kang CD. Potentiation of chemosensitivity in multidrug-resistant human leukemia CEM cells by inhibition of DNA-dependent protein kinase using wortmannin. Leuk Res 2000, 24:917-925. 10.1016/S0145-2126(00)00061-8, 11086175.
46. Ismail IH, Martensson S, Moshinsky D, Rice A, Tang C, Howlett A, McMahon G, Hammarsten O. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 2004, 23:873-882. 10.1038/sj.onc.1207303, 14661061.
47. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, Calvert AH, Newell DR, Smith GC, Curtin NJ. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006, 66:5354-5362. 10.1158/0008-5472.CAN-05-4275, 16707462.